Fluvoxamine Extended-Release Capsules Luvox CR Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Capsules
Available Strengths: Luvox CR
Reference Brands: Luvox(US); Fevarin(EU)
Category: Antipsychotropic Drugs
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain, helping regulate mood and behavior. The extended-release formulation offers once-daily dosing. It is primarily used to treat obsessive-compulsive disorder (OCD) and social anxiety disorder (SAD) in adults, improving both intrusive thoughts and anxiety symptoms.
Product Description: In the United States, fluvoxamine extended-release (ER) capsules are FDA-approved for the treatment of obsessive-compulsive disorder (OCD) and social anxiety disorder (SAD). As a selective serotonin reuptake inhibitor (SSRI), it carries a Boxed Warning for increased risk of suicidal thoughts in adolescents and young adults. Regulatory compliance includes GMP standards, bioequivalence data for generics, and strict labeling and safety reporting. Ongoing pharmacovigilance is required through FDA’s FAERS system. In the European Union, fluvoxamine is typically available in immediate-release tablet form, with the ER capsule less commonly approved. EU regulatory approval follows centralized or national procedures, with mandatory Risk Management Plans (RMPs), Periodic Safety Update Reports (PSURs), and comprehensive clinical data. For regulatory-ready sourcing, visit Pharmatradz.com.
Fluvoxamine Extended-Release Capsules — third party manufacturing & bulk supply
Fluvoxamine Extended-Release Capsules Luvox CR is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Fluvoxamine Extended-Release Capsules is supplied as Extended-Release Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Fluvoxamine Extended-Release Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Fluvoxamine Extended-Release Capsules →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Lithium Carbonate
Strength:
150 mg, 300 mg, 600 mg
Form: Tablets
Reference Brands: Lithobid (USA/LATAM), Priadel (EU)
View Details
Phenobarbital Sodium
Strength:
65 mg/mL, 130 mg/mL.
Form: Injection
Reference Brands: Generic formulations marketed under different names
View DetailsQuick Response Guaranteed | Verified Suppliers
